NIRVF (Nirvana Life Sciences) ROE %: 0.00% (As of Jan. 2026)


What is Nirvana Life Sciences ROE %?

Nirvana Life Sciences NIRVF ROE % is 0.00% as of Jan. 2026. The stock has 3 warning signs investors should review. Among 1,250 Biotechnology companies, Nirvana Life Sciences ranks worse than 79999.92% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Nirvana Life Sciences's annualized net income for the quarter that ended in Jan. 2026 was $-0.15 Mil. Nirvana Life Sciences's average Total Stockholders Equity over the quarter that ended in Jan. 2026 was $-0.84 Mil. Therefore, Nirvana Life Sciences's annualized ROE % for the quarter that ended in Jan. 2026 was N/A%.

The historical rank and industry rank for Nirvana Life Sciences's ROE % or its related term are showing as below:

NIRVF's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.26
* Ranked among companies with meaningful ROE % only.

Nirvana Life Sciences  (OTCPK:NIRVF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jan. 2026 )
=Net Income/Total Stockholders Equity
=-0.152/-0.84
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.152 / 0)*(0 / 0.015)*(0.015 / -0.84)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jan. 2026 )
=Net Income/Total Stockholders Equity
=-0.152/-0.84
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-0.152 / -0.156) * (-0.156 / -0.152) * (-0.152 / 0) * (0 / 0.015) * (0.015 / -0.84)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9744 * 1.0263 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Jan. 2026) net income data. The Revenue data used here is four times the quarterly (Jan. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Nirvana Life Sciences ROE % Related Terms


Nirvana Life Sciences ROE % Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences ROE % Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
ROE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NIRVF vs VRTX, REGN, ALNY: ROE % Comparison

For the Biotechnology subindustry, Nirvana Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nirvana Life Sciences ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's ROE % distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's ROE % falls into.



Nirvana Life Sciences ROE % Calculation

Nirvana Life Sciences's annualized ROE % for the fiscal year that ended in Apr. 2025 is calculated as

ROE %=Net Income (A: Apr. 2025 )/( (Total Stockholders Equity (A: Apr. 2024 )+Total Stockholders Equity (A: Apr. 2025 ))/ count )
=-0.262/( (-0.828+-1.061)/ 2 )
=-0.262/-0.9445
=N/A %

Nirvana Life Sciences's annualized ROE % for the quarter that ended in Jan. 2026 is calculated as

ROE %=Net Income (Q: Jan. 2026 )/( (Total Stockholders Equity (Q: Oct. 2025 )+Total Stockholders Equity (Q: Jan. 2026 ))/ count )
=-0.152/( (-1.169+-0.511)/ 2 )
=-0.152/-0.84
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Nirvana Life Sciences (NIRVF) has a ROE % of 0.00% as of Jan. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nirvana Life Sciences and its competitors. According to the industry distribution chart, Nirvana Life Sciences ranks #999999 out of 1250 companies in the Biotechnology industry.
Is Nirvana Life Sciences' ROE % too high?
Nirvana Life Sciences' current ROE % is 0.00%. Based on the distribution chart, Nirvana Life Sciences ranks #999999 out of 1250 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nirvana Life Sciences' ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nirvana Life Sciences ranks #999999 out of 1250 companies for ROE %. This places Nirvana Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nirvana Life Sciences and its competitors. Nirvana Life Sciences's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current ROE % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.